Melissa Burgess, MD
Medical Oncology · Pittsburgh, PANPI 1497982649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Aadi Bioscience, Inc. accounts for 69.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in PA, where the typical reported total is $2,595.
Across 3 payments — averaging $112.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$233
- Springworks Therapeutics, Inc.$105
Across 484 payments — averaging $4944.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$623K
- Incyte Corporation$341K
- Merck$333K
- Eli Lilly$319K
- PTC Therapeutics, Inc.$235K
- Deciphera Pharmaceuticals Inc.$147K
- plus $397K from 8 others
What the payments were for
- Food & beverage$338100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 2 | $233 |
| Springworks Therapeutics, Inc. | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$338 in reported general payments places this provider in the 25th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pazopanib Hcl | 52 | $469,189 |
| IbrancePalbociclib | 19 | $314,868 |
| KoselugoSelumetinib Sulfate | 22 | $276,555 |
| SorafenibSorafenib Tosylate | 31 | $132,156 |
| Sunitinib Malate | 19 | $85,288 |
| Imatinib Mesylate | 42 | $75,013 |
| XareltoRivaroxaban | 13 | $6,893 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 14 | $872 |
| Gabapentin | 25 | $788 |
| Ondansetron Hcl | 43 | $737 |
| Potassium Chloride | 12 | $610 |
| Dexamethasone | 19 | $280 |
| Levothyroxine Sodium | 24 | $256 |
| Anastrozole | 13 | $219 |
| Oxycodone Hcl | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Pittsburgh
- Adam BrufskyPittsburgh$1.3M
- John KirkwoodPittsburgh$102K
- Antoinette WozniakPittsburgh$50K
- Dulabh MongaPittsburgh$44K
- Priya RastogiPittsburgh$27K
- Carl JunePhiladelphia$9M
- Sramila AithalBensalem$682K
- Shayma KazmiPhiladelphia$619K
- Deric SaviorWynnewood$343K
- Marcia BrosePhiladelphia$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.